Nebenwirkungen · Humalog
Humalog Mix25 100 units/ml suspension for injection in vial Humalog Mix25 100 units/ml suspension for injection in cartridge Humalog Mix25 100 units/ml KwikPen suspension for injection in a pre-filled pen · Abschnitt 4.8 · PDF-Seite 19
HOS-085520 · Präparat HOS-083129
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-13T17:33:00Z · SHA-256 346311c779d97c64bfc351999eb6d3faf359f3deec2a8964d33b453a851cb74f · Passage 591ce3aa6d6555db7032d0551da929e990b92080da2928085827a75c666ec353 · Zeichen 2713–3027 im Abschnitt